HealthcareServices

Alzheimer’s Disease Diagnostic Market Future Outlook 2026: Key Drivers and Growth Potential

February 19, 2026February 19, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the alzheimer’s disease diagnostic market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Alzheimer’s Disease Diagnostic Market in 2030?

The alzheimer’s disease diagnostic market size has seen rapid expansion in recent years. It is anticipated to increase from $7.26 billion in 2025 to $8.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.6%. The historical expansion of this market can be linked to factors such as the increasing prevalence of alzheimer’s disease, enhanced awareness of neurodegenerative disorders, the embrace of MRI and PET imaging, the development of diagnostic centers and hospitals, and investment in cognitive assessment research.

The alzheimer’s disease diagnostic market size is forecast to expand significantly in the coming years. It is predicted to reach $11.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is primarily attributed to the development of novel biomarkers and imaging tracers, the integration of artificial intelligence for early diagnosis, an increase in government and private funding for Alzheimer’s research, the expansion of personalized medicine initiatives, and a rise in multi-center clinical trials. Major trends foreseen for this period include the increasing adoption of biomarker-based diagnostics, a growing utilization of neuroimaging techniques for early detection, an expansion in cognitive assessment testing, the broadening of genetic testing for Alzheimer’s risk assessment, and the integration of multi-modal diagnostic approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What Drivers Are Influencing Production Trends In The Alzheimer’s Disease Diagnostic Market?

The rising incidence of chronic ailments is anticipated to drive the expansion of the Alzheimer’s disease diagnostic market in the future. A strong link exists between chronic conditions like cardiovascular disease, diabetes, and hypertension and an elevated risk of Alzheimer’s and other forms of dementia, thus boosting the need for timely and precise diagnostic tools. A key contributor to the surge in chronic diseases is the prevalent adoption of inactive lifestyles, given that extensive epidemiological studies consistently demonstrate considerably higher occurrences of conditions such as diabetes and cardiovascular disease among individuals with low physical activity. Diagnostic tools for Alzheimer’s assist healthcare systems by allowing for prompt detection, enabling quick interventions, and directing patient care to decelerate the progression of the illness. As an illustration, in November 2023, data from Heritage Health Services, a US-based nonprofit specializing in healthcare research, indicated that 6.7 million Americans aged 65 or older were affected by Alzheimer’s dementia, with the prevalence rising with age: 5.0% for those 65–74 years old, 13.1% for 75–84 years, and 33.3% for individuals 85+ years. Projections suggest that by 2050, this figure will escalate to almost 13 million. Consequently, the growing incidence of chronic diseases is fueling the expansion of the Alzheimer’s disease diagnostic market.

Which Segments Are Gaining Traction In The Alzheimer’s Disease Diagnostic Market?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Which Trends Are Shaping Activity Within The Alzheimer’s Disease Diagnostic Market?

Leading companies in the alzheimer’s disease diagnostic market are focusing on advancements in blood-based biomarker tests, which are expected to streamline the diagnostic process for Alzheimer’s disease, lessening dependence on more invasive procedures and improving patient access to timely treatment. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a blood-based biomarker for Alzheimer’s pathology demonstrating clinical sensitivity and specificity. Traditional methods for cerebrospinal fluid (CSF) biomarkers, including positron emission tomography (PET) or lumbar puncture, are both costly, invasive, and not widely available. Additionally, this new test integrates Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s extensively tested p-Tau 217 antibodies, ensuring remarkable accuracy and a simpler process.

Who Are The Major Companies Operating In The Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Alzheimer’s Disease Diagnostic Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

Autism Spectrum Disorder Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795